請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/62663
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 鄭世榮 | |
dc.contributor.author | Wen-Ren Lin | en |
dc.contributor.author | 林文仁 | zh_TW |
dc.date.accessioned | 2021-06-16T16:06:53Z | - |
dc.date.available | 2016-09-24 | |
dc.date.copyright | 2013-09-24 | |
dc.date.issued | 2013 | |
dc.date.submitted | 2013-06-13 | |
dc.identifier.citation | 參考文獻
1. Douglas D. Damm, Jerry E. Bouquot, Brad W. Neville, Douglas D. Damm, Jerry Bouquot, Oral and Maxillofacial Pathology. 3rd ed. 2009. 315-76. 2. Shah, J., Head and Neck Surgery. 2nd ed. 2002. 143-234, 355-93,. 3. Ko YC, Huang YL, Lee CH, Chen MJ, Lin LM, Tsai CC., Betal quid chewing, smoking and alcohol consumption realted to oral cancer in Taiwan. J Oral Pathol Med, 1995. 24: p. 450-3. 4. Y.K Chen, H.C Huang, L.M Lin, C.C Lin, Primary oral squamous cell carcinoma: an analysis of 703 cases in southern Taiwan. Oral Oncol, 1999. 35(2): p. 173-9. 5. Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, Lin CH, Chen IH, Huang SF, Cheng AJ, Yen TC., Analysis of risk factors of predictive local tumor control in oral cavity cancer. Ann Surg Oncol, 2008. 15(3): p. 915-22. 6. Chen YJ, Chang JT, Liao CT, Wang HM, Yen TC, Chiu CC, Lu YC, Li HF, Cheng AJ., Head and neck cancer in the betel quid chewing area: recent advances in molecular carcinogenesis. Cancer Sci, 2008. 99(8): p. 1507-14. 7. Watts, J.M., The importance of the Plummer-Vinson syndrome in the aetiology of carcinoma of the upper gastrointestinal tract. Postgrad Med J, 1961. 37: p. 523-33. 8. Sankaranarayanan R, Mathew B, Varghese C, Sudhakaran PR, Menon V, Jayadeep A, Nair MK, Mathews C, Mahalingam TR, Balaram P, Nair PP., et al., Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncol, 1997. 33(4): p. 231-6. 9. Krogh, P., B. Hald, and P. Holmstrup, Possible mycological etiology of oral mucosal cancer: catalytic potential of infecting Candida albicans and other yeasts in production of N-nitrosobenzylmethylamine. Carcinogenesis, 1987. 8(10): p. 1543-8. 10. Dickenson, A.J., W.J. Currie, and B.S. Avery, Screening for syphilis in patients with carcinoma of the tongue. Br J Oral Maxillofac Surg, 1995. 33(5): p. 319-20. 11. Niv A, Sion-Vardi N, Gatot A, Nash M, Fliss DM., Identification and typing of human papillomavirus (HPV) in squamous cell carcinoma of the oral cavity and oropharynx. J Laryngol Otol, 2000. 114(1): p. 41-6. 12. Leemans, C.R., B.J. Braakhuis, and R.H. Brakenhoff, The molecular biology of head and neck cancer. Nat Rev Cancer, 2011. 11(1): p. 9-22. 13. Partridge M, Kiguwa S, Emilion G, Pateromichelakis S, A'Hern R, Langdon JD., New insights into p53 protein stabilisation in oral squamous cell carcinoma. Oral Oncol, 1999. 35(1): p. 45-55. 14. Sheu JJ, Hua CH, Wan L, Lin YJ, Lai MT, Tseng HC, Jinawath N, Tsai MH, Chang NW, Lin CF, Lin CC, Hsieh LJ, Wang TL, Shih IeM, Tsai FJ., Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. Cancer Res, 2009. 69(6): p. 2568-76. 15. Slaughter, D.P., H.W. Southwick, and W. Smejkal, Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer, 1953. 6(5): p. 963-8. 16. Zahorowska, B., P.J. Crowe, and J.L. Yang, Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs. J Cancer Res Clin Oncol, 2009. 135(9): p. 1137-48. 17. Wu, C., Heat shock transcription factors: structure and regulation. Annu Rev Cell Dev Biol, 1995. 11: p. 441-69. 18. Morimoto, R.I., Regulation of the heat shock transcriptional response: cross talk between a family of heat shock factors, molecular chaperones, and negative regulators. Genes Dev, 1998. 12(24): p. 3788-96. 19. Morano, K.A. and D.J. Thiele, Heat shock factor function and regulation in response to cellular stress, growth, and differentiation signals. Gene Expr, 1999. 7(4-6): p. 271-82. 20. Sorger, P.K. and H.R. Pelham, Yeast heat shock factor is an essential DNA-binding protein that exhibits temperature-dependent phosphorylation. Cell, 1988. 54(6): p. 855-64. 21. Wiederrecht, G., D. Seto, and C.S. Parker, Isolation of the gene encoding the S. cerevisiae heat shock transcription factor. Cell, 1988. 54(6): p. 841-53. 22. Clos J, Westwood JT, Becker PB, Wilson S, Lambert K, Wu C., Molecular cloning and expression of a hexameric Drosophila heat shock factor subject to negative regulation. Cell, 1990. 63(5): p. 1085-97. 23. Nover L, Scharf KD, Gagliardi D, Vergne P, Czarnecka-Verner E, Gurley WB., The Hsf world: classification and properties of plant heat stress transcription factors. Cell Stress Chaperones, 1996. 1(4): p. 215-23. 24. Nakai, A., New aspects in the vertebrate heat shock factor system: Hsf3 and Hsf4. Cell Stress Chaperones, 1999. 4(2): p. 86-93. 25. Leppa, S. and L. Sistonen, Heat shock response--pathophysiological implications. Ann Med, 1997. 29(1): p. 73-8. 26. McMillan DR, Xiao X, Shao L, Graves K, Benjamin IJ., Targeted disruption of heat shock transcription factor 1 abolishes thermotolerance and protection against heat-inducible apoptosis. J Biol Chem, 1998. 273(13): p. 7523-8. 27. Vuister GW, Kim SJ, Orosz A, Marquardt J, Wu C, Bax A., Solution structure of the DNA-binding domain of Drosophila heat shock transcription factor. Nat Struct Biol, 1994. 1(9): p. 605-14. 28. Sandqvist A, Bjork JK, Akerfelt M, Chitikova Z, Grichine A, Vourc'h C, Jolly C, Salminen TA, Nymalm Y, Sistonen L., Heterotrimerization of heat-shock factors 1 and 2 provides a transcriptional switch in response to distinct stimuli. Mol Biol Cell, 2009. 20(5): p. 1340-7. 29. Peteranderl, R. and H.C. Nelson, Trimerization of the heat shock transcription factor by a triple-stranded alpha-helical coiled-coil. Biochemistry, 1992. 31(48): p. 12272-6. 30. Peteranderl R, Rabenstein M, Shin YK, Liu CW, Wemmer DE, King DS, Nelson HC., Biochemical and biophysical characterization of the trimerization domain from the heat shock transcription factor. Biochemistry, 1999. 38(12): p. 3559-69. 31. Rabindran SK, Haroun RI, Clos J, Wisniewski J, Wu C., Regulation of heat shock factor trimer formation: role of a conserved leucine zipper. Science, 1993. 259(5092): p. 230-4. 32. Pattaramanon, N., N. Sangha, and A. Gafni, The carboxy-terminal domain of heat-shock factor 1 is largely unfolded but can be induced to collapse into a compact, partially structured state. Biochemistry, 2007. 46(11): p. 3405-15. 33. Newton EM, Knauf U, Green M, Kingston RE., The regulatory domain of human heat shock factor 1 is sufficient to sense heat stress. Mol Cell Biol, 1996. 16(3): p. 839-46. 34. Choi, Y., S. Asada, and M. Uesugi, Divergent hTAFII31-binding motifs hidden in activation domains. J Biol Chem, 2000. 275(21): p. 15912-6. 35. Green M, Schuetz TJ, Sullivan EK, Kingston RE., A heat shock-responsive domain of human HSF1 that regulates transcription activation domain function. Mol Cell Biol, 1995. 15(6): p. 3354-62. 36. Kline, M.P. and R.I. Morimoto, Repression of the heat shock factor 1 transcriptional activation domain is modulated by constitutive phosphorylation. Mol Cell Biol, 1997. 17(4): p. 2107-15. 37. Soncin F, Zhang X, Chu B, Wang X, Asea A, Ann Stevenson M, Sacks DB, Calderwood SK., Transcriptional activity and DNA binding of heat shock factor-1 involve phosphorylation on threonine 142 by CK2. Biochem Biophys Res Commun, 2003. 303(2): p. 700-6. 38. Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P, Mann M., Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell, 2006. 127(3): p. 635-48. 39. Lee YJ, Kim EH, Lee JS, Jeoung D, Bae S, Kwon SH, Lee YS., HSF1 as a mitotic regulator: phosphorylation of HSF1 by Plk1 is essential for mitotic progression. Cancer Res, 2008. 68(18): p. 7550-60. 40. Mayya V, Lundgren DH, Hwang SI, Rezaul K, Wu L, Eng JK, Rodionov V, Han DK., Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal, 2009. 2(84): p. ra46. 41. Olsen JV, Vermeulen M, Santamaria A, Kumar C, Miller ML, Jensen LJ, Gnad F, Cox J, Jensen TS, Nigg EA, Brunak S, Mann M., Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal, 2010. 3(104): p. ra3. 42. Knauf U, Newton EM, Kyriakis J, Kingston RE., Repression of human heat shock factor 1 activity at control temperature by phosphorylation. Genes Dev, 1996. 10(21): p. 2782-93. 43. Wang X, Grammatikakis N, Siganou A, Calderwood SK., Regulation of molecular chaperone gene transcription involves the serine phosphorylation, 14-3-3 epsilon binding, and cytoplasmic sequestration of heat shock factor 1. Mol Cell Biol, 2003. 23(17): p. 6013-26. 44. Wang X, Grammatikakis N, Siganou A, Stevenson MA, Calderwood SK., Interactions between extracellular signal-regulated protein kinase 1, 14-3-3epsilon, and heat shock factor 1 during stress. J Biol Chem, 2004. 279(47): p. 49460-9. 45. Hietakangas V, Anckar J, Blomster HA, Fujimoto M, Palvimo JJ, Nakai A, Sistonen L., PDSM, a motif for phosphorylation-dependent SUMO modification. Proc Natl Acad Sci U S A, 2006. 103(1): p. 45-50. 46. Anckar, J. and L. Sistonen, SUMO: getting it on. Biochem Soc Trans, 2007. 35(Pt 6): p. 1409-13. 47. Geiss-Friedlander, R. and F. Melchior, Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol, 2007. 8(12): p. 947-56. 48. Westerheide SD, Anckar J, Stevens SM, Sistonen L, Morimoto RI., Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1. Science, 2009. 323(5917): p. 1063-6. 49. Littlefield, O. and H.C. Nelson, A new use for the 'wing' of the 'winged' helix-turn-helix motif in the HSF-DNA cocrystal. Nat Struct Biol, 1999. 6(5): p. 464-70. 50. Liu, P.C. and D.J. Thiele, Modulation of human heat shock factor trimerization by the linker domain. J Biol Chem, 1999. 274(24): p. 17219-25. 51. Hoang AT, Huang J, Rudra-Ganguly N, Zheng J, Powell WC, Rabindran SK, Wu C, Roy-Burman P., A novel association between the human heat shock transcription factor 1 (HSF1) and prostate adenocarcinoma. Am J Pathol, 2000. 156(3): p. 857-64. 52. Jin, X., D. Moskophidis, and N.F. Mivechi, Heat shock transcription factor 1 is a key determinant of HCC development by regulating hepatic steatosis and metabolic syndrome. Cell Metab, 2011. 14(1): p. 91-103. 53. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 1989. 244(4905): p. 707-12. 54. Tan M, Li P, Klos KS, Lu J, Lan KH, Nagata Y, Fang D, Jing T, Yu D., ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis. Cancer Res, 2005. 65(5): p. 1858-67. 55. Zhao YH, Zhou M, Liu H, Ding Y, Khong HT, Yu D, Fodstad O, Tan M., Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth. Oncogene, 2009. 28(42): p. 3689-701. 56. Meng, L., V.L. Gabai, and M.Y. Sherman, Heat-shock transcription factor HSF1 has a critical role in human epidermal growth factor receptor-2-induced cellular transformation and tumorigenesis. Oncogene, 2010. 29(37): p. 5204-13. 57. Mendillo ML, Santagata S, Koeva M, Bell GW, Hu R, Tamimi RM, Fraenkel E, Ince TA, Whitesell L, Lindquist S., HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers. Cell, 2012. 150(3): p. 549-62. 58. Ishikawa N, Takano A, Yasui W, Inai K, Nishimura H, Ito H, Miyagi Y, Nakayama H, Fujita M, Hosokawa M, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y., Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res, 2007. 67(24): p. 11601-11. 59. Maruyama M, Yoshitake H, Tsukamoto H, Takamori K, Araki Y., Molecular expression of Ly6k, a putative glycosylphosphatidyl-inositol-anchored membrane protein on the mouse testicular germ cells. Biochem Biophys Res Commun, 2010. 402(1): p. 75-81. 60. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, Wong KK, Elledge SJ., A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell, 2009. 137(5): p. 835-48. 61. Dai C, Santagata S, Tang Z, Shi J, Cao J, Kwon H, Bronson RT, Whitesell L, Lindquist S., Loss of tumor suppressor NF1 activates HSF1 to promote carcinogenesis. J Clin Invest, 2012. 122(10): p. 3742-54. 62. Ishiwata J, Kasamatsu A, Sakuma K, Iyoda M, Yamatoji M, Usukura K, Ishige S, Shimizu T, Yamano Y, Ogawara K, Shiiba M, Tanzawa H, Uzawa K., State of heat shock factor 1 expression as a putative diagnostic marker for oral squamous cell carcinoma. Int J Oncol, 2012. 40(1): p. 47-52. 63. Dai C, Whitesell L, Rogers AB, Lindquist S., Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell, 2007. 130(6): p. 1005-18. 64. Yuspa, S.H., The pathogenesis of squamous cell cancer: lessons learned from studies of skin carcinogenesis--thirty-third G. H. A. Clowes Memorial Award Lecture. Cancer Res, 1994. 54(5): p. 1178-89. 65. Bossis I, Voutetakis A, Bei T, Sandrini F, Griffin KJ, Stratakis CA., Protein kinase A and its role in human neoplasia: the Carney complex paradigm. Endocr Relat Cancer, 2004. 11(2): p. 265-80. 66. Fantin, V.R., J. St-Pierre, and P. Leder, Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell, 2006. 9(6): p. 425-34. 67. O'Callaghan-Sunol, C. and M.Y. Sherman, Heat shock transcription factor (HSF1) plays a critical role in cell migration via maintaining MAP kinase signaling. Cell Cycle, 2006. 5(13): p. 1431-7. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/62663 | - |
dc.description.abstract | 中文摘要
背景 熱休克蛋白(heat shock proteins, 簡稱HSPs)扮演著伴護蛋白分子(molecular chaperones)的角色,藉由維持細胞內蛋白質的正常摺疊與恆定,這些熱休克蛋白保護細胞免於環境緊迫所造成的蛋白質結構性傷害,並對已受損害的蛋白質進行修復或水解,以恢復蛋白質正常的生理功能,維持蛋白質功能的平衡性。而熱休克轉錄因子1(Heat Shock Factor 1,簡稱HSF1),是一個82-k Da的轉錄因子,負責調節熱休克蛋白和其他逆境蛋白基因轉錄,引起熱休克反應的中樞。在一些熱休克的反應或是存在外在壓力下的環境,會強烈的活化這個轉錄因子的作用,以產生更多的熱休克蛋白幫助修復在惡劣環境中受到損害的一些蛋白質,好讓細胞得以在惡劣的環境中繼續存活下來。 腫瘤內的細胞,經常暴露在惡劣和變化迅速的微環境中。為了持續生長和發展,癌細胞必須能夠很有效率的適應這樣的微環境,就像前面所提及的生物體應付生存壓力時一樣,癌細胞也會發展出特定的機制來適應環境。許多研究都可以觀察到在不同的人類腫瘤中,如前列腺癌、肺癌、大腸癌、胰臟癌、子宮頸癌、膀胱癌及腦膜瘤等的表現量都有提高的情形。本研究欲探討HSF1於口腔癌病理組織中的表現量及與臨床各參數和存活時間的關係。 材料與方法 本研究利用免疫組織化學染色方法,探討HSF1於92例口腔鱗狀細胞癌(OSCC)、25例口腔上皮變異(OED)及35例正常口腔黏膜(NOM)中的表現,並以陽性染色指標Labeling index記錄其染色程度。利用卡方檢定(Chi-square test)、Kaplan-Meier 存活率方法及Cox proportional hazard regression model來分析HSF1的表現與口腔鱗狀細胞癌患者臨床病理參數及存活率之相關性,並試圖尋找影響存活時間的獨立預後因子。 結果 在正常口腔黏膜HSF1的平均陽性標記指數為12% (最低),口腔上皮變異組的平均陽性標記指數為34%,口腔癌組的平均陽性標記指數為54% (最高),從正常口腔黏膜、上皮變異至口腔癌的癌化過程,HSF1表現增加之情形已達統計意義(P < 0.001)。HSF1的表現和患者的腫瘤大小(T status)、淋巴結轉移與否(N status)、癌症臨床分期(Stage)有統計上相關。 各項臨床參數在Cox proportional hazard regression model分析中,單變數分析後發現,腫瘤大小、淋巴結轉移與否、腫瘤臨床分期及HSF1的陽性染色指標(LI)都與存活率有關;多變數分析腫瘤大小、淋巴結轉移與否及HSF1的陽性染色指標(LI)為影響存活時間的獨立因子(independent factor;p<0.05);HSF1陽性染色指標若>53%,影響病人存活的危險率(hazard ration)高達6.249倍(p=0.043)。 若以Kaplan-Meier plots來觀察臨床病理各項參數、HSF1的陽性染色指標與病人總存活時間(overall survival),經Log-Rank Test分析後,腫瘤大小、淋巴結轉移與否、腫瘤臨床分期均影響病人的存活時間,且達統計上之意義(p<0.05)。而本研究探討的HSF1的陽性染色指標(LI)若>53%,則明顯降低了口腔癌病人的存活率(p=0.044)。 結論 在本研究中,HSF1的陽性染色指標在口腔癌病理標本中的表現較高且具統計上意義,且與口腔細胞癌患者在臨床參數及存活時間有關。在口腔癌患者而言,HSF1的表現量較高者其存活時間較短;而HSF1在切片組織中的表現程度,或許可以做為口腔癌的預後指標(prognostic marker)。 | zh_TW |
dc.description.abstract | Abstract
Background HSPs function as molecular chaperones to restore protein homeostasis. Heat Shock Factor 1(HSF1) is an 82-k Da transcription factor that is strongly activated in response to heat shock and other forms of environmental and chemical stresses. HSF1 is responsible for expression of a large class of heat shock proteins, which protect cells from damage as a result of cellular insults, heat chock and oxidative stress. The tumor cell is usually exposed to the harsh environment. Heat Shock Factor 1(HSF1), master regulator of heat-shock proteins, facilitates the survival and proliferation of tumor cells under such conditions. Many types of highly malignant tumors express high levels of HSF1, including prostate, lung, colon, pancreas, cervix and meningioma. Our study shows that the over expression in OSCC and the correlation with the clinical, pathological parameters, and survival time. Materials and Methods Examined in this study were 92 specimens diagnosed as oral squamous cell carcinoma (OSCC) and 25 specimens of oral epithelial dysplasia (OED). 35 cases of normal oral mucosa (NOM) were also observed for comparison. With a HSF1 monoclonal antibody, immunohistochemistry (IHC) stain was performed for detecting expression of HSF1 in these tissue sections. The degree of positive staining was recorded and graded as labeling index (LI). Finally, the correlations between expression of HSF1, clinical and pathologic parameters, and the overall survival of OSCC patients were analyzed statistically via Chi-square test, Cox proportional hazard regression model, and Kaplan-Meier plots. Results The labeling index of HSF1 was significantly higher in OSCC specimens (p<0.001). The average LI of HSF1 in OSCC specimens was 54%. In OED specimens, the average LI was 34%. In NOM, the average LI was only 12%. Meanwhile, higher HSF1 LIs indicated larger tumor size (T3 and T4 status), nodal metastasis and later clinical stage (Stage 3 and stage 4). These results were all revealed with statistical significance (Chi-square test; p<0.05). As Cox proportional hazard regression model, the tumor size (T status), nodal metastasis (N status), clinical stage, and the LIs of HSF1 were statistically significant. Multivariate analysis revealed that tumor size (T status), nodal metastasis (N status) and the LIs of HSF1 were independent factors of patient survival (p<0.05). Kaplan-Meier survival analysis showed that patients had shorter survival time with advanced tumor sizes, nodal metastasis, later clinical staging, and high LIs of HSF1. Conclusions The expression of HSF1 was higher in OSCC specimen. The labeling index of HSF1 has strong correlation with several clinicopathological parameters and survival time. In OSCC patients, higher HSF1 expression seemed to indicate shorter overall survival. Judging from the above analysis, HSF1 is probably a potential prognostic factor of OSCC. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T16:06:53Z (GMT). No. of bitstreams: 1 ntu-102-R00422026-1.pdf: 842949 bytes, checksum: 565160f0db4ef7fdb8003a3b0425ac64 (MD5) Previous issue date: 2013 | en |
dc.description.tableofcontents | 目錄
致謝............................................................................................................................I 中文摘要...................................................................................................................II 英文摘要.................................................................................................................IV 第一章 序論及文獻回顧.............................................................................................. 1 1.1.口腔鱗狀細胞癌概論........................................................................................ 1 1.1.1口腔鱗狀細胞癌簡介................................................................................. 1 1.1.2口腔鱗狀細胞癌之流行病學......................................................................2 1.1.2.1口腔鱗狀細胞癌之全球流行病學.......................................................2 1.1.2.2.口腔鱗狀細胞癌之台灣地區流行病學及疾病特色...........................2 1.1.3口腔鱗狀細胞癌之危險因子及基因變異..................................................3 1.1.4口腔鱗狀細胞癌之臨床分期......................................................................5 1.1.5現行對口腔鱗狀細胞之治療及預後..........................................................6 1.1.6口腔癌前病變..............................................................................................7 1.2 HSF1概論...........................................................................................................9 1.2.1 HSF(Heat shock factor)簡介…..………......................................................9 1.2.2 HSF1之結構與功能....................................................................................9 1.2.3 HSF1之轉譯後修飾(post-translational modification)..............................11 1.2.3.1 HSF1的磷酸化作用…………….………………..............................11 1.2.3.2 HSF1的依賴磷酸化作用的泛素化作用…………………………...12 1.2.3.3 HSF1的乙醯化作用………………………………………………...13 1.3 HSF1與癌症之關係.........................................................................................13 1.3.1 HSF1於人類癌症之發現..... ....................................................................13 1.3.2 HSF1在致癌機轉上扮演的角色之研究…………………......................19 1.3.2.1 HSF1的缺乏抑制化學物質誘導皮膚致癌作用之研究…………...19 1.3.2.2 HSF1的缺乏抑制p53突變的腫瘤生成作用……...........................19 1.3.2.3 HSF1支持RAS基因進行轉化作用..................................................20 1.3.2.4 HSF1支持原致癌基因PDGF-B進行轉化作用……………………20 1.3.2.5 HSF1對於不同致癌機制的影響…………………………………...20 1.3.2.6 HSF1會調控訊息傳導……………………………………………...21 1.3.2.7 HSF1調節轉譯作用………………………………………………...21 1.3.2.8 HSF1調節葡萄糖的代謝作用……………………………………...22 1.3.2.9 HSF1參與細胞遷移能力的表現…………………………………...23 第二章 材料與方法.....................................................................................................24 2.1實驗樣本............................................................................................................24 2.2標本之固定與包埋............................................................................................24 2.3免疫組織化學染色(immunohistochemistry stain) ...........................................24 2.3.1反應原理.....................................................................................................24 2.3.2初級抗體的選擇.........................................................................................25 2.3.3 抗原抗體結合之偵測系統.......................................................................25 2.3.4實驗步驟....................................................................................................26 2.4免疫組織化學染色之觀察與記錄...................................................................28 2.4.1觀察............................................................................................................28 2.4.2染色程度之定量........................................................................................28 2.4.3臨床變數之記錄........................................................................................28 2.4.4統計分析....................................................................................................29 第三章 結果.................................................................................................................31 3.1 HSF1於口腔鱗狀細胞癌(OSCC)、口腔上皮變異(OED)及正常口腔上皮(NOM)之表現..................................................................................................31 3.2 HSF1免疫組織化學染色結果與患者臨床及組織病理各項參數之關係....32 3.3 HSF1免疫組織化學染色與臨床、組織病理參數之單變數、多變數分析….36 3.4 HSF1表現與存活時間分析.............................................................................36 第四章 討論.................................................................................................................38 第五章 結論.................................................................................................................42 第六章 附表與附圖.....................................................................................................43 參考文獻.........................................................................................................................54 | |
dc.language.iso | zh-TW | |
dc.title | Heat Shock Factor 1於口腔鱗狀細胞癌中之表現 | zh_TW |
dc.title | Expression of Heat Shock Factor 1 in oral squamous cell carcinoma | en |
dc.type | Thesis | |
dc.date.schoolyear | 101-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 郭彥彬,江俊斌 | |
dc.contributor.oralexamcommittee | 張龍昌 | |
dc.subject.keyword | 熱休克轉錄因子1,口腔鱗狀細胞癌,口腔上皮變異, | zh_TW |
dc.subject.keyword | HSF1,oral squamous cell carcinoma,oral epithelial dysplasia, | en |
dc.relation.page | 59 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2013-06-13 | |
dc.contributor.author-college | 牙醫專業學院 | zh_TW |
dc.contributor.author-dept | 臨床牙醫學研究所 | zh_TW |
顯示於系所單位: | 臨床牙醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-102-1.pdf 目前未授權公開取用 | 823.19 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。